"Too Young" Can Be a Dangerous Assumption When It Comes to Prostate Cancer
Prostate cancer is often described as an older man's disease. And statistically, that description largely holds true. The risk rises significantly with age, and most diagnoses occur in men over 50.
But "mostly older men" does not mean "only older men."
And when it comes to cancer detection, assumptions about age can sometimes delay important conversations.
Today, prostate cancer is the most commonly diagnosed cancer in UK men, with around 1 in 8 men developing the disease during their lifetime. Each year, approximately 12,000 men in the UK die from prostate cancer — around one every hour.
Despite this, many younger men never consider their prostate health at all.
Age Matters — But It's Not The Only Risk Factor
The majority of prostate cancers are diagnosed in men over 65. For men under 45, the overall risk remains low.
But risk is not distributed evenly.
Certain groups can face significantly higher risk earlier in life, including men who:
- Have a father or brother diagnosed with prostate cancer
- Are of Black ethnicity
- Carry certain inherited genetic mutations, such as BRCA2
- Have multiple family members with prostate or breast cancer
Men with a first-degree relative affected by prostate cancer may have two to three times the risk of developing the disease themselves.
For Black men, the risk of developing prostate cancer is around double that of white men.
Because of this, several international guidelines suggest that discussions around prostate cancer testing may begin earlier for higher-risk individuals — sometimes from age 40-45.
Why Early Detection Matters
When prostate cancer is detected early, outcomes are extremely good.
Men diagnosed while the disease is localised to the prostate have a five-year survival rate of over 99%.
However, if the cancer spreads to other parts of the body, survival rates fall dramatically — to around 30-40% for metastatic disease.
This difference highlights why awareness and early conversations matter.
Detecting prostate cancer before it spreads can dramatically change both treatment options and long-term outcomes.
The Screening Debate
Unlike some other cancers, the UK does not currently run a national screening programme for prostate cancer.
This is largely because the commonly used PSA blood test is not perfect. While it can help detect prostate cancer, it can also produce false positives or identify slow-growing cancers that may never cause harm.
As a result, some men may undergo investigations or treatment that ultimately prove unnecessary.
For this reason, most clinical guidance emphasises informed decision-making rather than blanket screening.
Men aged 50 and over in the UK can request a PSA test from their GP after discussing the potential benefits and risks.
However, internationally there is growing recognition that risk-based screening discussions may be appropriate earlier for some individuals.
The Reality: Awareness Often Starts Too Late
One challenge with prostate cancer is that it often develops silently.
Early stages may produce no symptoms at all. When symptoms do appear — such as urinary changes, blood in urine, or unexplained bone pain — the disease may already be more advanced.
This is why clinicians increasingly emphasise risk awareness rather than waiting for symptoms.
Knowing your family history, understanding your personal risk factors, and being willing to start conversations with a healthcare professional can make a meaningful difference.
A More Nuanced Conversation
The goal is not to encourage unnecessary testing for every younger man.
But nor should we dismiss prostate cancer risk purely because of age.
A more balanced approach is emerging internationally: one that recognises that age, genetics, ethnicity, and family history all shape an individual's risk profile.
For some men, that conversation about prostate health may reasonably begin earlier than expected.
Because when it comes to prostate cancer, one thing remains consistently true:
The earlier it is detected, the more options there are.